Pharmacogenomic association between a variant in SLC47A1 gene and therapeutic response to metformin in type 2 diabetes

被引：91

作者：

Tkac, I. ^{[1
]}

Klimcakova, L. ^{[2
]}

Javorsky, M. ^{[1
]}

Fabianova, M. ^{[1
]}

Schroner, Z. ^{[1
]}

Hermanova, H. ^{[2
]}

Babjakova, E. ^{[1
]}

Tkacova, R. ^{[3
]}

机构：

[1] Safarik Univ, Fac Med, Dept Internal Med 4, Kosice, Slovakia

[2] Safarik Univ, Fac Med, Dept Med Biol, Kosice, Slovakia

[3] Safarik Univ, Fac Med, Dept Resp Med & TB, Kosice, Slovakia

来源：

DIABETES OBESITY & METABOLISM | 2013年 / 15卷 / 02期

关键词：

glycaemic control; metformin; pharmacogenetics; type; 2; diabetes; OCT1;

D O I：

10.1111/j.1463-1326.2012.01691.x

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

Pharmacogenetic studies revealed that variants in genes related to the pharmacokinetics of metformin were associated with glucose-lowering effect of metformin. The aim of this study was to investigate possible associations of the variants in genes encoding organic cationic transporterssolute carrier family 22, members A1, A2 (SLC22A1, SLC22A2) and solute carrier family 47, member A1 (SLC47A1) with response to metformin in type 2 diabetes. One hundred forty-eight drug-naive patients with type 2 diabetes were included in the study. Genotyping for SLC22A1 rs622342, SLC22A2 rs316019 and SLC47A1 rs2289669 variants was performed using real-time PCR with subsequent melting-curve analysis. SLC47A1 rs2289669 genotype was significantly associated with the reduction in haemoglobin A1c (HbA1c) after 6?months. Twenty percentage of patients with diabetes that are homozygous for A-allele of SLC47A1 had twofold reduction in HbA1c in comparison with the patients carrying G-allele (GG?+?GA: 0.55 +/- 0.09% vs. AA: 1.10 +/- 0.18%, p?=?0.018). In conclusion, the results of this study might have in future practical implication in personalised treatment of patients with type 2 diabetes.

引用

页码：189 / 191

页数：3

共 11 条

[1]

Amer Diabet Assoc, 2006, DIABETES CARE, V29, pS43

[2]

Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus [J].

Becker, M. L. ;

Visser, L. E. ;

van Schaik, R. H. N. ;

Hofman, A. ;

Uitterlinden, A. G. ;

Stricker, B. H. C. .

PHARMACOGENOMICS JOURNAL, 2009, 9 (04) :242-247

[3]

Genetic Variation in the Multidrug and Toxin Extrusion 1 Transporter Protein Influences the Glucose-Lowering Effect of Metformin in Patients With Diabetes: A Preliminary Study [J].

Becker, Matth S. L. ;

Visser, Loes E. ;

van Schaik, Ron H. N. ;

Hofman, Albert ;

Uitterlinden, Andre G. ;

Stricker, Bruno H. Ch. .

DIABETES, 2009, 58 (03) :745-749

[4]

Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin [J].

Chen, Ying ;

Li, Shuanglian ;

Brown, Chaline ;

Cheatham, Stephen ;

Castro, Richard A. ;

Leabman, Maya K. ;

Urban, Thomas J. ;

Chen, Ligong ;

Yee, Sook Wah ;

Choi, Ji Ha ;

Huang, Yong ;

Brett, Claire M. ;

Burchard, Esteban G. ;

Giacomini, Kathleen M. .

PHARMACOGENETICS AND GENOMICS, 2009, 19 (07) :497-504

[5]

Clinical Pharmacokinetics of Metformin [J].

Graham, Garry G. ;

Punt, Jeroen ;

Arora, Manit ;

Day, Richard O. ;

Doogue, Matthew P. ;

Duong, Janna K. ;

Furlong, Timothy J. ;

Greenfield, Jerry R. ;

Greenup, Louise C. ;

Kirkpatrick, Carl M. ;

Ray, John E. ;

Timmins, Peter ;

Williams, Kenneth M. .

CLINICAL PHARMACOKINETICS, 2011, 50 (02) :81-98

[6]

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) [J].

Inzucchi, S. E. ;

Bergenstal, R. M. ;

Buse, J. B. ;

Diamant, M. ;

Ferrannini, E. ;

Nauck, M. ;

Peters, A. L. ;

Tsapas, A. ;

Wender, R. ;

Matthews, D. R. .

DIABETOLOGIA, 2012, 55 (06) :1577-1596

[7]

Common Variants in 40 Genes Assessed for Diabetes Incidence and Response to Metformin and Lifestyle Intervention in the Diabetes Prevention Program [J].

Jablonski, Kathleen A. ;

McAteer, Jarred B. ;

de Bakker, Paul I. W. ;

Franks, Paul W. ;

Pollin, Toni I. ;

Hanson, Robert L. ;

Saxena, Richa ;

Fowler, Sarah ;

Shuldiner, Alan R. ;

Knowler, William C. ;

Altshuler, David ;

Florez, Jose C. .

DIABETES, 2010, 59 (10) :2672-2681

[8]

Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms [J].

Schwabedissen, Henriette E. Meyer Zu ;

Verstuyft, Celine ;

Kroemer, Heyo K. ;

Becquemont, Laurent ;

Kim, Richard B. .

AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2010, 298 (04) :F997-F1005

[9]

Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics [J].

Shu, Y. ;

Brown, C. ;

Castro, R. A. ;

Shi, R. J. ;

Lin, E. T. ;

Owen, R. P. ;

Sheardown, S. A. ;

Yue, L. ;

Burchard, E. G. ;

Brett, C. M. ;

Giacomini, K. M. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 (02) :273-280

[10]

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) [J].

Turner, RC ;

Holman, RR ;

Stratton, IM ;

Cull, CA ;

Matthews, DR ;

Manley, SE ;

Frighi, V ;

Wright, D ;

Neil, A ;

Kohner, E ;

McElroy, H ;

Fox, C ;

Hadden, D .

LANCET, 1998, 352 (9131) :854-865

← 1 2 →